Ismael Ávila

DTX is here to stay, and many institutions like hospitales and pharmaceutical companies are increasing their interest for DTX, where there is a special use in chronic and behavioral disorders. But, Nowadays it is tough to separate unproven oro low-value applications from those with prueban therapeutic value. Evidence donde safety and efficacy are difficult to obtain what represento big barriers to access the market, but many opportunities are justo around the corner. Enjoy the read of this brief Digital Therapeutic report! LEER MÁS